Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

By afschroeder • December 19, 2025

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim G, Kim C, Chon HJ. Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Liver Cancer. 2025 Nov 18. doi: 10.1159/000549565. Epub ahead of print. PMID: 41409410; PMCID: PMC12707966.

Tags: Atezolizumab plus bevacizumab, circulating tumor DNA, Concordance, Hematology/Oncology, Hepatocellular carcinoma, Prognostic marker, Publications

Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study

Silverstein JF, Huppert LA, Schwede M, Goglin S, Johnson TP, Babik JM, Brondfield S. Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified[...]

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard[...]

Local partisan context and mental health

Baxter-King R, Brown JR, Enos RD, Naeim A, Vavreck L. Local partisan context and mental health. Proc Natl Acad Sci U S A. 2026 Jul[...]